Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer rheumatoid arthritis drug meets targets in phase III trial

Pfizer rheumatoid arthritis drug meets targets in phase III trial

7th March 2011

Pfizer has reported a successful conclusion to its second phase III clinical trial of tofacitinib, a developmental treatment for rheumatoid arthritis.

Data from the Oral Sync trial showed that Pfizer's drug was able to deliver statistically significant changes in reducing signs and symptoms compared to placebo, thus meeting its primary efficacy endpoint.

The results were consistent with those collated from previous studies, with the treatment also delivering improved physical function among users.

Tofacitinib was formerly known as tasocitinib and functions by targeting the intracellular signalling pathways operating as hubs in the inflammatory cytokine network, rather than extracellular targets.

It has been used to treat more than 4,000 patients during the clinical development process thus far, with the current Oral trial programme utilising subjects from 35 countries across more than 350 sites.

Last week, Pfizer announced that it has received European approval to launch Xiapex, a clinically-proven new therapy for Dupuytren's contracture.ADNFCR-8000103-ID-800445690-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.